The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children

Molluscum Contagiosum Clinical Trial

Official title:

The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04476186
• Other study ID #: site of study assiut U H
• Status: Recruiting
• Phase: N/A
• Start date: June 15, 2020
• Est. completion date: December 30, 2021

Study information

• Verified date: July 2020
• Source: Assiut University
• Contact: Hamdy Gomaa
• Phone: 00201000882184
• Email: dhamdy2003[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators will study the effectiveness of acyclovir in the treatment of molluscum contagiosum in assiut university hospital - dermatological out patient clinic the treatment group will receive acyclovir 200 mg 5 times per day the controlled group will receive local KOH solution

Description:

Study population:

Site of the study: The outpatient dermatological clinic in Assiut university hospital.

Participants: children (2 -16) years' old attending dermatological clinic in Assiut university hospital and their parents.

Methodology in details:

1. We will use the social media as " Facebook" to invite patient to visit the clinic and follow up them due to the protective measures of covid 19.

2. Diagnosis of the patient with molluscum contagiosum according to the clinical picture

3. Collecting data including personal and clinical data through interviewing the patient and his or her parents

4. Pictures of the lesions will be taken before and after treatment after patient consent.

5. We will Randomly assigning the patient to either treatment group or controlled group according to simple random table

6. Prescribing the treatment according to the patient group

7. Follow up of the patient after 1 weak and each week according to the response to treatment or presence of complication

Inclusion criteria:

Children (5 -15) years old with Molluscum contagiosum.

Exclusion criteria:

1. Molluscum contagiosum with Inflamed spot

2. Known immune compromised children

3. Molluscum lesion in the eye lid.

4. Children with renal impairment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: December 30, 2021
• Est. primary completion date: December 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 16 Years

Eligibility

Inclusion Criteria:

• Children (2 -16) years old with Molluscum contagiosum.

Exclusion Criteria:

• Molluscum contagiosum with Inflamed spot Known immune compromised children Molluscum lesion in the eye lid. Children with renal impairment.

Related Conditions & MeSH terms

• Molluscum Contagiosum

Intervention

Drug:
• Acyclovir
oral syrp
• KOH 10 %
solution for local application

Locations

Country	Name	City	State
Egypt	Hamdy Gomaa	Assiut	New Assiut City

Sponsors (4)

Lead Sponsor	Collaborator
Dalia Mahran	assistant professor Ghada M. Khafagy, Dr. Marwa Diaaeldeen Abbass Hasan, Prof. Dr. Emad Taha Abd-Elahim Ebiad

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of patient with complete clearance of all molluscum lesions.	we will measure the percentage of patient recovered from all lesion	3 month for each participant